Literature DB >> 26501422

NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway.

Wenwen Xu1, Junjie Gu1, Qingling Ren1, Yanqiu Shi1, Qinhua Xia1, Jing Wang1, Suli Wang2, Yingchun Wang2, Jinhua Wang3.   

Abstract

It has been reported that nuclear factor of activated T cells (NFATC1) was up-regulated in cancers mediating malignant behaviors. However, the role of NFATC1 in ovarian cancer has not been elucidated. In the present study, we undertook to explore the clinicopathological significance of NFATC1 expression and the mechanism by which NFATC1 works in ovarian cancer. Expression status of NFATC1 was examined using immunohistochemistry. Both knockdown and re-expression of NFATC1 on ovarian cancer cells were employed to observe the effect overgrowth. It was found that NFATC1 was significantly overexpressed in ovarian cancer tissues in comparison with paired normal control tissues and that overexpression of NFATC1 was significantly associated with metastasis and poor prognosis on clinical tissue level. In in vitro ovarian cancer cell lines, we found that NFATC1 can promote proliferation up-regulating c-myc through activation of ERK1/2/p38/MAPK signal pathway. Together, the results we obtained demonstrated that NFATC1 played oncogenic role in ovarian cancer. Mechanistically, NFATC1 promoted growth of ovarian cancer cells up-regulating c-myc through activation of ERK1/2/p38/MAPK signal pathway, suggesting that NFATC1 might be used as a therapeutic target for ovarian cancer.

Entities:  

Keywords:  C-myc; ERK1/2; NFATC1; Ovarian cancer; Proliferation

Mesh:

Substances:

Year:  2015        PMID: 26501422     DOI: 10.1007/s13277-015-4245-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma.

Authors:  Shuhuai Wang; Xinmei Kang; Shouqiang Cao; Hui Cheng; Di Wang; Jingshu Geng
Journal:  Dig Dis Sci       Date:  2012-06-22       Impact factor: 3.199

2.  Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway.

Authors:  Malte Buchholz; Alexandra Schatz; Martin Wagner; Patrick Michl; Thomas Linhart; Guido Adler; Thomas M Gress; Volker Ellenrieder
Journal:  EMBO J       Date:  2006-07-27       Impact factor: 11.598

3.  The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.

Authors:  Takashi Kawahara; Eiji Kashiwagi; Hiroki Ide; Yi Li; Yichun Zheng; Hitoshi Ishiguro; Hiroshi Miyamoto
Journal:  Prostate       Date:  2015-01-28       Impact factor: 4.104

4.  Activation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms.

Authors:  P Tripathi; Y Wang; M Coussens; K R Manda; A M Casey; C Lin; E Poyo; J D Pfeifer; N Basappa; C M Bates; L Ma; H Zhang; M Pan; L Ding; F Chen
Journal:  Oncogene       Date:  2013-04-29       Impact factor: 9.867

5.  NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells.

Authors:  Alexander Köenig; Thomas Linhart; Katrin Schlengemann; Kristina Reutlinger; Jessica Wegele; Guido Adler; Garima Singh; Leonie Hofmann; Steffen Kunsch; Thomas Büch; Eva Schäfer; Thomas M Gress; Martin E Fernandez-Zapico; Volker Ellenrieder
Journal:  Gastroenterology       Date:  2009-11-06       Impact factor: 22.682

6.  Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion.

Authors:  Tsukasa Oikawa; Atsuko Nakamura; Nobuyuki Onishi; Taketo Yamada; Koichi Matsuo; Hideyuki Saya
Journal:  Cancer Res       Date:  2013-06-28       Impact factor: 12.701

7.  NFAT promotes carcinoma invasive migration through glypican-6.

Authors:  Gary K Yiu; Aura Kaunisto; Y Rebecca Chin; Alex Toker
Journal:  Biochem J       Date:  2011-11-15       Impact factor: 3.857

8.  Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1.

Authors:  Takashi Kawahara; Eiji Kashiwagi; Hiroki Ide; Yi Li; Yichun Zheng; Yurina Miyamoto; George J Netto; Hitoshi Ishiguro; Hiroshi Miyamoto
Journal:  Oncotarget       Date:  2015-01-30

9.  Reporting research antibody use: how to increase experimental reproducibility.

Authors:  Matthew A Helsby; Joe R Fenn; Andrew D Chalmers
Journal:  F1000Res       Date:  2013-07-10

10.  The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.

Authors:  Daniel Weissinger; Katrin E Tagscherer; Stephan Macher-Göppinger; Axel Haferkamp; Nina Wagener; Wilfried Roth
Journal:  Mol Cancer       Date:  2013-10-10       Impact factor: 27.401

View more
  15 in total

1.  Dioscin suppresses the viability of ovarian cancer cells by regulating the VEGFR2 and PI3K/AKT/MAPK signaling pathways.

Authors:  Xianqing Guo; Xiao Ding
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

Review 2.  Calcineurin in development and disease.

Authors:  Lei Chen; Min Song; Chunyan Yao
Journal:  Genes Dis       Date:  2021-03-15

3.  DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.

Authors:  Lian Li; Hong Zheng; Yubei Huang; Caiyun Huang; Shuang Zhang; Jing Tian; Pei Li; Anil K Sood; Wei Zhang; Kexin Chen
Journal:  Carcinogenesis       Date:  2017-08-01       Impact factor: 4.741

4.  Akirin2 regulates proliferation and differentiation of porcine skeletal muscle satellite cells via ERK1/2 and NFATc1 signaling pathways.

Authors:  Xiaoling Chen; Yanliu Luo; Zhiqing Huang; Gang Jia; Guangmang Liu; Hua Zhao
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

5.  Expression, prognosis and functional role of Thsd7a in esophageal squamous cell carcinoma of Kazakh patients, Xinjiang.

Authors:  Zhichao Hou; Abulajiang Abudureheman; Lei Wang; Ayshamgul Hasim; Julaiti Ainiwaer; Haiping Zhang; Madiniyat Niyaz; Halmurat Upur; Ilyar Sheyhidin
Journal:  Oncotarget       Date:  2017-04-08

6.  Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.

Authors:  Kai Zhang; Weihan Wang; Lingli Chen; Yulin Liu; Jiali Hu; Fei Guo; Wenyan Tian; Yingmei Wang; Fengxia Xue
Journal:  Oncol Rep       Date:  2020-07-02       Impact factor: 3.906

7.  Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer.

Authors:  Bing Xin; Kai-Qiang Ji; Yi-Si Liu; Xiao-Dong Zhao
Journal:  J Ovarian Res       Date:  2019-08-09       Impact factor: 4.234

8.  MiR-17-5p and miR-20a promote chicken cell proliferation at least in part by upregulation of c-Myc via MAP3K2 targeting.

Authors:  Xiaofei Zhang; He Song; Shupei Qiao; Jing Liu; Tianyu Xing; Xiaohong Yan; Hui Li; Ning Wang
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

9.  NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway.

Authors:  Sanrong Xu; Penghao Shu; Song Zou; Xiaofeng Shen; Yuanqian Qu; Yong Zhang; Kang Sun; Jin Zhang
Journal:  Cancer Med       Date:  2018-08-07       Impact factor: 4.452

10.  Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

Authors:  Alejandro Ruiz-Patiño; Oscar Arrieta; Andrés F Cardona; Claudio Martín; Luis E Raez; Zyanya L Zatarain-Barrón; Feliciano Barrón; Luisa Ricaurte; María A Bravo-Garzón; Luis Mas; Luis Corrales; Leonardo Rojas; Lorena Lupinacci; Florencia Perazzo; Carlos Bas; Omar Carranza; Carmen Puparelli; Manglio Rizzo; Rossana Ruiz; Christian Rolfo; Pilar Archila; July Rodríguez; Carolina Sotelo; Carlos Vargas; Hernán Carranza; Jorge Otero; Luis E Pino; Carlos Ortíz; Paola Laguado; Rafael Rosell
Journal:  Thorac Cancer       Date:  2019-12-12       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.